To print: Select File and then Print from your browser's menu

Title: Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk

"Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk"

OTTAWA, Ontario -- July 18, 2008 -- Health Canada is warning patients not to use the prescription drug Sandoz Timolol Ophthalmic Solution in 0.25% and 0.5% strengths because some bottles may contain more of the active ingredient (timolol maleate) than indicated on the label, exposing patients to an increased risk of adverse events. Sandoz Timolol Ophthalmic Solution 0.25% and 0.5% are eye drops taken for the treatment of increased intraocular pressure and glaucoma. Potential adverse events may include red eye, eye irritation, inflammation of the eyelids and/or cornea, drooping of the upper eyelid, double vision, dizziness, headache, abnormally slow heartbeat, abnormally low blood pressure, shortness of breath, difficulty breathing, and cardiac failure. Patients taking either Sandoz Timolol Ophthalmic Solution 0.25% or 0.5% eye drops should discontinue use and consult their healthcare practitioner immediately to ensure that treatment of intraocular pressure is not interrupted. Patients should return the product to their pharmacist for safe disposal. The manufacturer, Sandoz Canada Inc., is recalling the products, and Health Canada is continuing to monitor the effectiveness of this recall. Patients requiring more information about this advisory can contact Health Canada's public enquiries line at 613-957-2991 or toll free at 1-866-225-0709. To date, no cases of adverse reactions linked to the use of this product have been reported in Canada. To report a suspected adverse reaction to this product, please contact the Canada Vigilance Program of Health Canada by one of the following methods: Telephone: 1-866-234-2345 Facsimile: 1-866-678-6789 Canada Vigilance Program Mail: Marketed Health Products Directorate Ottawa, Ontario, AL 0701C K1A 0K9 E-mail: CanadaVigilance@hc-sc.gc.ca SOURCE: Health Canada

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.